Organon & Co. (OGN) Stock
1 member of Congress disclosed 1 trade in OGN since 2026: 0 purchases and 1 sale, most recently Kevin Hern (sale, Aug 5, 2026). 5 of the hedge funds AlphaScala tracks reported OGN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $46.61M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.
Which members of Congress traded Organon & Co. (OGN)?
Most recent: Kevin Hern (sale, Aug 5, 2026); records start Aug 5, 2026.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-08-05 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all OGN political trades →Which hedge funds own OGN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.44M | $46.61M | -49% |
| Marshall Wace | 828K | $11.21M | -11% |
| D.E. Shaw David Shaw | 719K | $9.73M | -73% |
| Citadel Ken Griffin | 344K | $4.66M | -83% |
| Blackstone | 105K | $1.43M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Organon & Co. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 5, 26 | Drinane Juliana Papa | Head of Mfg & Supply | SELL | 14.8K | $200K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →OGN price chart
Powered by TradingViewWhat does Organon & Co. do?
Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology, and chronic disease management. The company offers products such as contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, alongside a range of mature branded medicines for pain, respiratory conditions, and cardiovascular disorders. Organon & Co. operates across major geographies, with significant presence in Europe, Canada, the United States, Asia Pacific, and Japan. It emphasizes research and development to advance therapies in women’s health and biosimilars, while maintaining a strong lineup of established products that provide reliable treatment options worldwide. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. plays a vital role in the pharmaceutical sector by bridging innovation with accessible healthcare solutions for diverse patient populations.